STXK - ETF AI Analysis

Top Page

Strive 2000 ETF (STXK)

Rating:64Neutral

Price Target:―

The Strive 2000 ETF (STXK) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Sanmina-Sci stands out as a key contributor to the fund's rating due to its strong financial performance and strategic growth, while Columbia Banking System also adds value with its robust valuation metrics and successful strategic initiatives. However, holdings like Avidity Biosciences and Cytokinetics weigh on the rating due to financial instability and profitability concerns. A notable risk for this ETF is its exposure to companies with valuation challenges, which could impact overall performance in volatile market conditions.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid gains so far this year, indicating strong overall momentum.

Low Expense Ratio

With a low expense ratio, this ETF allows investors to keep more of their returns compared to higher-cost funds.

Broad Sector Diversification

The ETF is spread across multiple sectors, reducing the risk of being overly exposed to a single industry.

Negative Factors

High Geographic Concentration

The ETF is heavily focused on U.S. companies, offering limited exposure to international markets.

Underperforming Holdings

Some top holdings, such as Columbia Banking System, have shown weak performance, which could drag on overall returns.

Small Cap Focus

Many holdings are smaller companies, which can be more volatile and sensitive to market fluctuations.

STXK vs. SPDR S&P 500 ETF (SPY)

AUM67.59M

RegionNorth America

Expense Ratio0.18%

Beta1.00

IssuerStrive

Inception DateNov 10, 2022

Dividend Yield1.26%

Asset ClassEquity

Index TrackedBloomberg US 600 Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume5,024

30 Day Avg. Volume8,445

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

39.71

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering593

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

STXK Summary

The Strive 2000 ETF (Ticker: STXK) is designed to invest in small-cap companies, which are smaller businesses with high growth potential. It follows the Bloomberg US 2000 index and includes a wide range of industries, such as technology, financials, and healthcare. Some of its top holdings include well-known companies like Lyft and Cognex. This ETF is a good option for investors looking to diversify their portfolio and tap into the growth opportunities of emerging companies. However, small-cap stocks can be more volatile, meaning their prices can go up and down quickly, so investors should be prepared for potential risks.

How much will it cost me?The Strive 2000 ETF (Ticker: STXK) has an expense ratio of 0.18%, meaning you’ll pay $1.80 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on small-cap stocks with a broad-based approach while keeping costs relatively low for investors.

What would affect this ETF?The Strive 2000 ETF (STXK), with its focus on U.S. small-cap stocks across diverse sectors like technology, financials, and consumer cyclical, could benefit from economic growth and innovation in these industries, as smaller companies often thrive during expansion periods. However, small-cap stocks are more sensitive to economic downturns, interest rate hikes, and market volatility, which could negatively impact the ETF's performance. Additionally, regulatory changes or sector-specific challenges in areas like healthcare or energy could influence the fund's growth potential.

STXK Top 10 Holdings

The Strive 2000 ETF (STXK) is leaning heavily on the agility of small-cap stocks, with a diverse mix of sectors and a U.S.-centric focus. Guardant Health is a standout, rising on strong momentum despite financial challenges, while Avidity Biosciences also shows promise with bullish trends countering profitability concerns. On the flip side, Coeur Mining and Lyft are lagging, with operational setbacks and valuation pressures weighing on performance. The fund’s broad exposure to sectors like technology, healthcare, and financials offers growth potential, but the mixed performance of its top holdings highlights the inherent volatility of the small-cap space.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
	―	0.79%	$532.67K	―	―	―
GH	Guardant Health	0.59%	$399.13K	$13.21B	193.64%	61 Neutral
HL	Hecla Mining Company	0.56%	$379.71K	$12.60B	248.33%	74 Outperform
CDE	Coeur Mining	0.46%	$313.99K	$11.08B	162.96%	69 Neutral
RNA	Avidity Biosciences	0.44%	$300.43K	$10.82B	121.08%	60 Neutral
ARWR	Arrowhead Pharmaceuticals	0.44%	$299.07K	$9.52B	220.78%	57 Neutral
SANM	Sanmina-Sci	0.43%	$289.85K	$8.76B	100.66%	79 Outperform
COLB	Columbia Banking System	0.42%	$284.26K	$8.75B	-0.44%	77 Outperform
MOD	Modine	0.41%	$279.34K	$7.36B	5.91%	68 Neutral
LNC	Lincoln National	0.41%	$277.61K	$8.56B	36.75%	71 Outperform

STXK Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

32.99

Positive

100DMA

32.57

Positive

200DMA

30.69

Positive

Market Momentum

MACD

0.39

Negative

RSI

61.41

Neutral

STOCH

82.56

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXK, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.97, equal to the 50-day MA of 32.99, and equal to the 200-day MA of 30.69, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 61.41 is Neutral, neither overbought nor oversold. The STOCH value of 82.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXK.

STXK Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
STXK	―	―	$67.59M	0.18%	―
ITWO	―	―	$98.52M	0.55%	―
FLQS	―	―	$71.28M	0.35%	―
AFSM	―	―	$67.94M	0.75%	―
FSCC	―	―	$65.60M	0.36%	―
BKSE	―	―	$61.97M	0.04%	―

Performance Comparison

STXK

Strive 2000 ETF

34.09

1.53

4.70%

ITWO

ProShares Russell 2000 High Income ETF

―

FLQS

Franklin LibertyQ U.S. Small Cap Equity ETF

―

AFSM

First Trust Active Factor Small Cap ETF

―

FSCC

Federated Hermes MDT Small Cap Core ETF

―

BKSE

BNY Mellon US Small Cap Core Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents